Impact of intranasal fentanyl in nurse initiated protocols for sickle cell vaso-occlusive pain episodes in a pediatric emergency department
To the Editor:
Although pain is a universal feature of sickle cell disease (SCD), there is limited evidence to guide management for vasoocclusive pain episodes (VOE). In 2014, the National Heart, Lung, and Blood Institutes (NHLBI) published new guidelines recommending rapid evaluation and treatment of VOE in the acute care setting, with timely pain assessments and repeat analgesia as needed to control pain. Despite these guidelines, delays in administration of parenteral analgesia are common in pediatric emergency departments (ED). 1 Fentanyl is a potent, synthetic narcotic analgesic with a rapid onset and short duration of action. It is a strong agonist at the μ-opioid receptors, approximately 100 times more potent than morphine. Intranasal fentanyl (INF) has an onset of action of about [5] [6] [7] [8] [9] [10] minutes, peaking within 30 minutes. INF 1.4 mcg/kg equates to intravenous (IV) fentanyl 1 mcg/kg (approx. 70% bioavailability), [2] [3] [4] [5] [6] and can provide rapid and powerful analgesia in the ED without the need for IV access. Current evidence suggests that INF is a safe and Delays in delivery of analgesia for VOE in children with SCD have been reported in the literature, 3 demonstrating a need to seek methods to optimize pain control. INF represents a strategy to allow for more rapid parenteral opioid delivery that circumvents time-delays for IV access. In our study, we were able to adhere to the NHLBI guidelines which recommend delivery of the first dose of parenteral opioids within 30 minutes of triage or 60 minutes of registration in the acute care setting. 5 In a recently published randomized placebocontrolled trial involving children with SCD and moderate-severe pain, subjects randomized to INF had a greater decrease in median pain score at 20 minutes but not at 10 or 30 minutes. 4 This observation suggests that short-acting INF is best used for rapid pain relief as a temporizing bridge during IV access until longer-acting parenteral opioids are provided, as done in this study.
We did not find a difference in admission rates between those who received INF compared to historical controls. However, INF was implemented within a nursing-driven protocol for the assessment and management of pain associated with VOE, which has been shown to codes. The utilization of imaging studies which could lead to diagnosis of VTE was identified using current procedural terminology code.
Imaging studies of interests were duplex ultrasound of the extremity veins (DUV), ventilation-perfusion scan (V/Q scan), computed tomography pulmonary angiography (CTPA), and computed tomography of chest with intravenous contrast (CTC). CTC was included because it could detect pulmonary embolisms (PEs) incidentally albeit the study was ordered for other purposes.
The prevalence of VTE among cancer patients during ED visits was estimated. Multivariable logistic regression analysis was used to estimate the effect of VTE status on subsequent hospital admission, mortality risk, and total hospital costs. Higher total hospital costs was defined as greater than the 75th percentile of the study population (> $43 964). A two-sided P value < .05 was considered statistically significant.
There were 6 330 322 ED visits by cancer patients included in our study. The median age was 70 (interquartile range: 58-80) and CORRESPONDENCE E207
